Recruiting
Phase 2
Phase 3

Brepocitinib

Sponsor:

Priovant Therapeutics, Inc.

Code:

NCT07532603

Conditions

Lichen Planopilaris

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Oral Brepocitinib

Placebo

Study Details

Brief summary:

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Conditions

Lichen Planopilaris

Study ID

NCT07532603

Start date

Mar 19, 2026

Status verified date

Jul, 2026

Completion date

Jul 31, 2029

Anticipated

Primary completion date

Dec 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age ≥ 18 years
2. Scalp biopsy consistent with LPP
3. Active and symptomatic LPP at screening and baseline-
4. Weight > 40 kg to < 130 kg with BMI ≤ 45 kg/m2

Exclusion Criteria:

1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection

Study Design

Enrollment

342 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Brepocitinib Dose Level 1

placebo comparator: Placebo

Interventions

Oral Brepocitinib

Oral

Placebo

Oral

Primary outcome measure

  • Proportion of participants achieving IGA score 0/1 and ≥ 2-step reduction from baseline at Week 24 [ Time Frame: Week 24 ]

Central Contacts and Locations

Central contacts

Clinical Trial Administrator

(212) 634-9743clinicaltrials@priovant.com

Locations

Clinical Trial Site

Recruiting

Birmingham, Alabama, United States, 35244

Clinical Trial Site

Recruiting

Phoenix, Arizona, United States, 85006

Clinical Trial Site

Recruiting

Scottsdale, Arizona, United States, 85259

Clinical Trial Site

Recruiting

Irvine, California, United States, 92617

Clinical Trial Site

Recruiting

Oakland, California, United States, 94611

Clinical Trial Site

Recruiting

Sacramento, California, United States, 95823

Clinical Trial Site

Recruiting

San Francisco, California, United States, 94115

Clinical Trial Site

Recruiting

Denver, Colorado, United States, 80237

Clinical Trial Site

Recruiting

Farmington, Connecticut, United States, 06032

Clinical Trial Site

Recruiting

New Haven, Connecticut, United States, 06519

Clinical Trial Site

Recruiting

Miami, Florida, United States, 33136

Clinical Trial Site

Recruiting

Chicago, Illinois, United States, 60611

Clinical Trial Site

Recruiting

Skokie, Illinois, United States, 60077

Clinical Trial Site

Recruiting

Clarksville, Indiana, United States, 47129

Clinical Trial Site

Recruiting

Indianapolis, Indiana, United States, 46250

Clinical Trial Site

Recruiting

Leawood, Kansas, United States, 66211

Clinical Trial Site

Recruiting

Louisville, Kentucky, United States, 40241

Clinical Trial Site

Recruiting

Boston, Massachusetts, United States, 02115

Clinical Trial Site

Recruiting

Burlington, Massachusetts, United States, 01805

Clinical Trial Site

Recruiting

Ann Arbor, Michigan, United States, 48103

Clinical Trial Site

Recruiting

Ann Arbor, Michigan, United States, 48109

Clinical Trial Site

Recruiting

Medina, Minnesota, United States, 55340

Clinical Trial Site

Recruiting

Minneapolis, Minnesota, United States, 55455

Clinical Trial Site

Recruiting

Kansas City, Missouri, United States, 66103

Clinical Trial Site

Recruiting

Lee's Summit, Missouri, United States, 64064

Clinical Trial Site

Recruiting

Lebanon, New Hampshire, United States, 03766

Clinical Trial Site

Recruiting

New Hyde Park, New York, United States, 11042

Clinical Trial Site

Recruiting

New York, New York, United States, 10451

Clinical Trial Site

Recruiting

Durham, North Carolina, United States, 27713

Clinical Trial Site

Recruiting

Cleveland, Ohio, United States, 44195

Clinical Trial Site

Recruiting

Columbus, Ohio, United States, 43213

Clinical Trial Site

Recruiting

Medina, Ohio, United States, 44256

Clinical Trial Site

Recruiting

Portland, Oregon, United States, 97210

Clinical Trial Site

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Clinical Trial Site

Recruiting

Charleston, South Carolina, United States, 29425

Clinical Trial Site

Recruiting

Murfreesboro, Tennessee, United States, 37128

Clinical Trial Site

Recruiting

Smyrna, Tennessee, United States, 37167

Clinical Trial Site

Recruiting

Austin, Texas, United States, 78613

Clinical Trial Site

Recruiting

Austin, Texas, United States, 78660

Clinical Trial Site

Recruiting

Cedar Park, Texas, United States, 78613

Clinical Trial Site

Recruiting

Prosper, Texas, United States, 75078

Clinical Trial Site

Recruiting

Tyler, Texas, United States, 75703

Clinical Trial Site

Recruiting

Murray, Utah, United States, 84107

Clinical Trial Site

Recruiting

Norfolk, Virginia, United States, 23502

Clinical Trial Site

Recruiting

Richmond, Virginia, United States, 23235

Clinical Trial Site

Recruiting

Roanoke, Virginia, United States, 24016

Clinical Trial Site

Recruiting

Mill Creek, Washington, United States, 98012

Clinical Trial Site

Recruiting

Edmonton, Alberta, Canada, T6G1C3

Clinical Trial Site

Recruiting

Guelph, Ontario, Canada, N1L0B7

Clinical Trial Site

Recruiting

London, Ontario, Canada, M5M3Z8

Clinical Trial Site

Recruiting

Toronto, Ontario, Canada, L4B1A5

Clinical Trial Site

Recruiting

Toronto, Ontario, Canada, N6H5L4

More Information

Sponsor

Priovant Therapeutics, Inc.

Last update posted

Jul 8, 2026

Last verified

Jul, 2026

Keywords

  • brepocitinib
  • lichen planopilaris

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Priovant Therapeutics, Inc. on 2026-07-08.